The estimated Net Worth of Jesus B Mantas is at least $919 mil dollars as of 9 February 2021. Mr. Mantas owns over 898 units of Biogen Inc stock worth over $585,922 and over the last 5 years he sold BIIB stock worth over $0. In addition, he makes $333,286 as Independent Director at Biogen Inc.
Jesus has made over 1 trades of the Biogen Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 898 units of BIIB stock worth $239,766 on 9 February 2021.
The largest trade he's ever made was buying 898 units of Biogen Inc stock on 9 February 2021 worth over $239,766. On average, Jesus trades about 128 units every 0 days since 2019. As of 9 February 2021 he still owns at least 2,943 units of Biogen Inc stock.
You can see the complete history of Mr. Mantas stock trades at the bottom of the page.
Jesus B. Mantas serves as Independent Director of the Company. Mr. Mantas is the Managing Partner and General Manager leading worldwide strategy, offerings, digital platforms, innovation and thought leadership for IBM Global Business Services, the $17 billion unit of IBM that helps global leading enterprises design, transform and operate their businesses with digital and cloud technologies. He also serves on the board of IBM Services, the world largest technology services provider, and co-chairs the IBM Hispanic diversity council. Prior to his current role, he led globally multiple units in IBM, including Cognitive Process Transformation, Business Consulting and Global Process Services. From 2010 to 2014 Mr. Mantas lived in Brazil and led IBM Global Business Services in Latin America. From 2006 through 2010 he was Vice President of IBM Enterprise Sector in North America. Prior to joining IBM, Mr. Mantas was a partner in the High Technology practice of PricewaterhouseCoopers Consulting and an officer in the Air Force of Spain. Mr. Mantas serves in the World Economic Forum Global Artificial Intelligence Council and has been recognized as Top 25 Global Consulting Leader, Top 100 Hispanic IT Executive and Great Minds in STEM. He has degrees in telecommunications, software engineering and business administration from the Polytechnic University of Madrid and has served as professor at the Paul Merage School of Business, University of California Irvine.
As the Independent Director of Biogen Inc, the total compensation of Jesus Mantas at Biogen Inc is $333,286. There are 18 executives at Biogen Inc getting paid more, with Michel Vounatsos having the highest compensation of $18,159,900.
Jesus Mantas is 51, he's been the Independent Director of Biogen Inc since 2019. There are 21 older and 2 younger executives at Biogen Inc. The oldest executive at Biogen Inc is Stelios Papadopoulos, 72, who is the Independent Chairman of the Board.
Jesus's mailing address filed with the SEC is BIOGEN INC., 225 BINNEY ST., CAMBRIDGE, MA, 02142.
Over the last 21 years, insiders at Biogen Inc have traded over $166,883,156 worth of Biogen Inc stock and bought 665,319 units worth $183,001,783 . The most active insiders traders include Adam Koppel, Alexander J Denner y Stelios Papadopoulos. On average, Biogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of $2,343,090. The most recent stock trade was executed by Priya Singhal on 30 August 2024, trading 1,668 units of BIIB stock currently worth $332,082.
through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili
Biogen Inc executives and other stock owners filed with the SEC include: